Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial

BACKGROUND: Standard therapy for human epidermal growth factor receptor 2 (HER2)-mutant non-small-cell lung cancer (NSCLC) is lacking. The clinical benefits with pan-HER inhibitors (afatinib, neratinib, and dacomitinib), anti-HER2 antibody drug conjugate (ADC) trastuzumab emtansine, and an emerging...

Descripción completa

Detalles Bibliográficos
Autores principales: Ai, Xinghao, Song, Zhengbo, Jian, Hong, Zhou, Zhen, Chen, Zhiwei, Yu, Yongfeng, Li, Ziming, Lu, Shun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8444597/
https://www.ncbi.nlm.nih.gov/pubmed/34530760
http://dx.doi.org/10.1186/s12885-021-08759-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8444597/
https://www.ncbi.nlm.nih.gov/pubmed/34530760
http://dx.doi.org/10.1186/s12885-021-08759-8

Ejemplares similares